Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
July 18, 2023 by springer.com
Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
Vaping cessation is virtually unexplored. The efficacy and safety of varenicline for vaping cessation has not been studied and rigorous research is required to advance best practice and outcomes for people who use electronic cigarettes (EC) and want to quit. The objective is to evaluate the efficacy and safety of varenicline (1 mg BID, administered for 12 weeks, with follow-up to week 24) combined with vaping cessation counseling in exclusive daily EC users intending to quit vaping.